We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Polyphor AG (POLN) CHF2

Sell:1.50 CHF Buy:1.60 CHF Change: 0.018 CHF (1.21%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
Sell:1.50 CHF
Buy:1.60 CHF
Change: 0.018 CHF (1.21%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
Sell:1.50 CHF
Buy:1.60 CHF
Change: 0.018 CHF (1.21%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Polyphor AG is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.

Contact details

Address:
Hegenheimermattweg 125
ALLSCHWIL
4123
Switzerland
Telephone:
+41 (61) 5671600
Website:
https://www.polyphor.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
POLN
ISIN:
CH0106213793
Market cap:
18.30 million CHF
Shares in issue:
12.35 million
Sector:
Biotechnology
Exchange:
SIX Swiss Exchange
Country:
Switzerland
Currency:
Swiss Franc
Indices:
Swiss All Share Index

Key personnel

  • Gokhan Batur
    Chief Executive Officer, Member of the Executive Committee
  • Hernan Levett
    Chief Financial Officer, Member of the Executive Committee
  • Daniel Obrecht
    Chief Scientific Officer, Member of the Executive Committee
  • Franziska Mueller
    Head of Human Resources, Member of the Executive Committee
  • Frank Weber
    Chief Medical and Development Officer, Member of the Executive Committee

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.